Fundraising Fox
Mineralys Therapeutics
NASDAQ: MLYSRadnor, US · Founded 2019 · Delaware corporation · 10 known investors
Find your way into Mineralys Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
Ask John Halamka to introduce you to Alex Gold
You →John · together at Harvard Clinical Research Institute →Alex
Sign up to find every way you can get introduced to Mineralys Therapeutics
- Your email: who you already know at Mineralys Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Mineralys Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
Founders & leadership
Board
Investors · 10
How we know: a partner's Signal profile · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: SR One Capital Management's portfolio page · Not right? Tell us
How we know: Ysios Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$118M disclosed across 1 of 3 rounds · 1900–2022
▶$118MraisedJun 2022 · 23 investors · PharmaceuticalsRule 506(b)
- Brian Taylor SlingsbyDirector
- Olivier LitzkaDirector
- Derek DiRoccoDirector
- Adam LevyExecutive Officer
- Jon CongletonExecutive Officer, Director
- Srinivas AkkarajuDirector
- Alexander AsamDirector
- Takeshi TakahashiDirector
- Offering amount
- $118M
- Amount sold
- $118M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Mineralys Therapeutics went on to found or lead other companies.
Related companies · 5
Companies working in the same space as Mineralys Therapeutics.
Frequently asked questions
- What does Mineralys Therapeutics do?
- Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.
- Who are Mineralys Therapeutics's investors?
- Mineralys Therapeutics's investors include Andera Partners, HBM Healthcare Investments, HBM Partners, Samsara BioCapital, SR One Capital Management, Ysios Capital, Adams Street Partners, Boulder Ventures and 2 more.
- How much funding has Mineralys Therapeutics raised?
- Mineralys Therapeutics has disclosed $118M raised across 1 of its 3 known rounds.
- Where is Mineralys Therapeutics headquartered?
- Mineralys Therapeutics is headquartered in Radnor, US.